TherapeuticsMD (TXMD) Equity Ratio (2010 - 2026)

TherapeuticsMD has reported Equity Ratio for 17 years, with the latest figure at 0.72 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio rose 2.63% year-over-year to 0.72; the trailing twelve-month figure through Mar 2026 stood at 0.72 (up 2.63% YoY), and the FY2025 full-year result was 0.71, up 1.24% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.72, up from 0.71 in the prior quarter.
• The five-year high for Equity Ratio was 0.72 in Q1 2026, with the low at 1.05 in Q1 2022.
• Historically, Equity Ratio has averaged 0.44 across 5 years, with a median of 0.68 in 2024.
• Annual changes were most pronounced in 2022 — Equity Ratio tumbled 2561.13% — and 2023, when it jumped 425.92%.
• TherapeuticsMD's Equity Ratio stood at 0.39 in 2022, then jumped by 74.06% to 0.68 in 2023, then gained by 4.26% to 0.71 in 2024, then advanced by 1.24% to 0.71 in 2025, then climbed by 0.56% to 0.72 in 2026.
• The last three Equity Ratio figures came in at 0.72 (Q1 2026), 0.71 (Q4 2025), and 0.71 (Q3 2025), per Business Quant data.